IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.379
AS - Asia 1.156
EU - Europa 628
SA - Sud America 185
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.400
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.341
SG - Singapore 501
CN - Cina 233
VN - Vietnam 192
SE - Svezia 161
BR - Brasile 135
IE - Irlanda 132
IT - Italia 105
HK - Hong Kong 95
DE - Germania 50
FR - Francia 42
ZA - Sudafrica 35
NL - Olanda 31
IN - India 26
AT - Austria 23
GB - Regno Unito 23
CA - Canada 21
TR - Turchia 20
ID - Indonesia 18
RU - Federazione Russa 15
AR - Argentina 13
BD - Bangladesh 13
JP - Giappone 12
MX - Messico 12
EC - Ecuador 11
PL - Polonia 10
CL - Cile 6
PK - Pakistan 6
PY - Paraguay 6
BE - Belgio 5
FI - Finlandia 5
BO - Bolivia 4
CO - Colombia 4
ES - Italia 4
IL - Israele 4
IQ - Iraq 4
PH - Filippine 4
UA - Ucraina 4
AL - Albania 3
KE - Kenya 3
MA - Marocco 3
SA - Arabia Saudita 3
TH - Thailandia 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
CI - Costa d'Avorio 2
GR - Grecia 2
JO - Giordania 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
RO - Romania 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BG - Bulgaria 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GY - Guiana 1
HN - Honduras 1
IR - Iran 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
ZM - Zambia 1
Totale 3.400
Salva come PNG Salva come JPEG
Città #
Singapore 288
Ashburn 210
Chandler 195
Dublin 129
San Jose 122
Dallas 105
Santa Clara 102
Hong Kong 91
Ho Chi Minh City 61
New York 56
Beijing 55
Shanghai 49
Ann Arbor 35
Hanoi 34
Boardman 33
Lauterbourg 32
Council Bluffs 30
Johannesburg 30
Los Angeles 26
Princeton 23
Bremen 20
Vienna 19
Da Nang 17
Columbus 14
Dearborn 14
Parma 14
Des Moines 13
Jakarta 13
Wilmington 11
Munich 10
São Paulo 10
Atlanta 9
Buffalo 9
The Dalles 9
Tokyo 9
Warsaw 9
Curitiba 8
Mexico City 8
Milan 8
Nanjing 8
Frankfurt am Main 7
Haiphong 7
Izmir 7
Moscow 7
Pune 7
Biên Hòa 6
Brooklyn 6
Changsha 6
Chicago 6
London 6
Quito 6
Rio de Janeiro 6
Amsterdam 5
Bologna 5
Brussels 5
Helsinki 5
Houston 5
Montreal 5
Nuremberg 5
Ankara 4
Belo Horizonte 4
Busseto 4
Can Tho 4
Cape Town 4
Dhaka 4
Guangzhou 4
Kunming 4
Nanchang 4
Orem 4
Pavia 4
Phoenix 4
Toronto 4
Trieste 4
Washington 4
Baghdad 3
Boston 3
Buenos Aires 3
Denver 3
Francisco Morato 3
Fremont 3
Grafing 3
Guayaquil 3
Hebei 3
Hải Dương 3
Istanbul 3
Jinan 3
Marseille 3
Nanning 3
Naples 3
Porto Alegre 3
Redondo Beach 3
Redwood City 3
Santiago 3
Shenyang 3
Sumaré 3
Thái Bình 3
Tirana 3
Woodbridge 3
Abidjan 2
Alvorada 2
Totale 2.186
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 160
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 157
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 154
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 149
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 147
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 135
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 135
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 134
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 125
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 123
Cystic brain metastases and RET fusion in lung cancer 122
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 119
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 118
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 118
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 116
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 113
Exploring the role of respiratory microbiome in lung cancer: A systematic review 112
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 104
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 103
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 97
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 91
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial 67
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 66
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 60
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 59
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis 55
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making 52
ALK fusions turn sixteen in lung cancer: a review on their biology, detection and therapy 43
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 43
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>P 30
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era 28
Non-small-cell lung cancer: how to manage BRAF-mutated disease 24
Totale 3.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 6 9 2
2021/2022150 2 2 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/2025645 6 30 35 47 99 94 25 12 88 57 49 103
2025/20261.597 132 91 215 166 298 120 172 65 226 112 0 0
Totale 3.460